Matrix Metalloproteinase 13-deficient Mice Are Resistant to Osteoarthritic Cartilage Erosion but Not Chondrocyte Hypertrophy or Osteophyte Development
Overview
Affiliations
Objective: To investigate the role of matrix metalloproteinase 13 (MMP-13; collagenase 3) in osteoarthritis (OA).
Methods: OA was surgically induced in the knees of MMP-13-knockout mice and wild-type mice, and mice were compared. Histologic scoring of femoral and tibial cartilage aggrecan loss (0-3 scale), erosion (0-7 scale), and chondrocyte hypertrophy (0-1 scale), as well as osteophyte size (0-3 scale) and maturity (0-3 scale) was performed. Serial sections were stained for type X collagen and the MMP-generated aggrecan neoepitope DIPEN.
Results: Following surgery, aggrecan loss and cartilage erosion were more severe in the tibia than femur (P<0.01) and tibial cartilage erosion increased with time (P<0.05) in wild-type mice. Cartilaginous osteophytes were present at 4 weeks and underwent ossification, with size and maturity increasing by 8 weeks (P<0.01). There was no difference between genotypes in aggrecan loss or cartilage erosion at 4 weeks. There was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks (P<0.02). Cartilaginous osteophytes were larger in knockout mice at 4 weeks (P<0.01), but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints.
Conclusion: Our findings indicate that structural cartilage damage in a mouse model of OA is dependent on MMP-13 activity. Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.
Yanoshita M, Hirose N, Nishiyama S, Tsuboi E, Kubo N, Kita D In Vitro Cell Dev Biol Anim. 2025; .
PMID: 40064746 DOI: 10.1007/s11626-024-01008-9.
Cxcl9-deficiency attenuates the progression of post-traumatic osteoarthritis in mice.
Donat A, Xie W, Jiang S, Brylka L, Schinke T, Rolvien T Inflamm Res. 2025; 74(1):48.
PMID: 40047894 PMC: 11885341. DOI: 10.1007/s00011-025-02013-8.
Ariyoshi W, Takeuchi J, Mitsugi S, Koga A, Nagai-Yoshioka Y, Yamasaki R Biomedicines. 2025; 13(2).
PMID: 40002789 PMC: 11852791. DOI: 10.3390/biomedicines13020376.
Clinical and omics biomarkers in osteoarthritis diagnosis and treatment.
Deng M, Tang C, Yin L, Jiang Y, Huang Y, Feng Y J Orthop Translat. 2025; 50:295-305.
PMID: 39911590 PMC: 11795539. DOI: 10.1016/j.jot.2024.12.007.
Kang D, Lee J, Yook G, Jeong S, Shin J, Kim M Nat Commun. 2025; 16(1):1094.
PMID: 39904978 PMC: 11794700. DOI: 10.1038/s41467-024-55085-1.